Remerciez-le!

Remerciez @Admin pour avoir partagé cet document gratuitement, de la manière la plus simple, en partageant sur les réseaux sociaux.

1 NovaLisa TM Toxoplasma gondii IgG Avidity Test 0483 Enzyme immunoassay for th

1 NovaLisa TM Toxoplasma gondii IgG Avidity Test 0483 Enzyme immunoassay for the avidity determination of IgG-class antibodies to Toxoplasma gondii in human serum Enzymimmunoassay zur Bestimmung der Avidität von IgG-Antikörpern gegen Toxoplasma gondii in Humanserum Only for in-vitro diagnostic use English: Page 2 to 4 Deutsch: Seite bis Francais: Page à Italiano: da Pagina a Espanol: Página a For further languages please contact our authorized distributors. Bibliography / Literatur / Bibliographie / Page / Seite / Page / 6 Bibliografia / Bibliografía Pagina / Página Symbols Key / Symbolschlüssel / Page / Seite / Page / 7 Explication des symboles / Legenda / Símbolos Pagina / Página Summary of Test Procedure/ Kurzanleitung Testdurchführung/ Résumé de la procedure de test/ Page / Seite / Page/ 8 Schema della procedura/ Resumen de la técnica / Pagina / Página _______________________________________________________________________ Product number: TOXGA460 (96 Determinations) _______________________________________________________________________ 2 ENGLISH 0483 1.INTRODUCTION The avidity determination is a diagnostic method which is used to differentiate a recent (acute) and a more distant (past) infection with Toxoplasma gondii in patient sera. Avidity is the binding force of the antibody (serum specimen) with the corresponding antigen. Low avid IgG antibodies in the early stage of infection can be differentiated from high avid antibodies associated with a past infection. The determination of IgG antibody avidity is an additional analysis to the classic serology in regard to the status of a Toxoplasma gondii infection. 2. INTENDED USE The NovaTec Toxoplasma gondii IgG avidity test is intended to differentiate between past and acute infection. 3. PRINCIPLE OF THE ASSAY Microtiter strip wells coated with Toxoplasma antigen are incubated with diluted serum specimen (dual pipetting). After washing one well is incubated with avidity reagent and the corresponding well with washing buffer. In this step the low avidity antibodies are removed from the antigens whereas the high avidity ones are still bound to the specific antigens. Anti human IgG labelled with peroxidase is added. The immuncomplex is visualized with TMB to give a blue reaction product. Stop solution is added to stop the reaction and changing the colour of the reaction product into yellow. Absorbance at 450 nm is read using an ELISA microwell plate reader. 4. MATERIALS 4.1. Reagents supplied Avidity Reagent* : 1 bottle containing 15 ml of an Urea solution, coloured blue, ready to use, white cap. Performance control ** : 1 bottle containing 3 ml of a high avidity diluted serum coloured yellow, ready to use, green cap * contains 0.1 % Bronidox L ** contains 0.02 % Kathon and 0.02% Bronidox 4.2. Additional materials required but not provided NovaTec CE-labelled Toxoplasma gondii IgG ELISA, [REF] TOXG0460 5. STABILITY AND STORAGE The reagents are stable up to the expiry date stated on the label when stored at +2...+8 °C. After first opening the reagents are stable up to the expiry date. 6. REAGENT PREPARATION The avidity reagent and performance control are ready to use. Crystallisation of the avidity reagent may occur at low temperature. Therefore it is very important to bring the avidity reagent and control to room temperature (+20…+25°C) before starting the test run! 7. ASSAY PROCEDURE Use procedure and test preparation as mentioned in the NovaTec Toxoplasma gondii IgG package insert [REF] TOXG0460 The performance of the avidity test is different as follows: Dual pipetting of the serum samples and control: A clean, disposable tip should be used for dispensing the control and serum samples. 1. Wells A1/A2 are used for the substrate blank. 2. Dispense 100 µl performance control in wells B1/B2. 3. Dispense 100µl diluted serum sample (1+100) in wells C1/C2. Dispense 100µl diluted serum sample (1+100) in wells D1/D2 etc. Cover the wells with foil. 4. Incubate for 1 hour ± 5 min at 37°C ± 1°C 5. When incubation has been completed, remove the foil, aspirate the content of the wells and wash each well three times with 300µl of washing solution. Avoid overflows from the reaction wells. The soak time between each wash cycle should be >5 sec. At the end carefully remove remaining fluid by tapping strips on tissue paper prior to the next step! (See step 4, package insert Toxoplasma gondii IgG , [REF] TOXG0460) Note: Washing is critical! Insufficient washing results in poor precision. 6. Dispense 100µl of Avidity reagent in wells B1, C1, D1, E1 etc. Dispense 100µl of diluted (1+19) Washing solution in wells B2, C2, D2, E2 etc. 7. Incubate for exactly 5 min at room temperature (+20 to +25°C). 8. Repeat step 5. 9. Dispense 100 µl Toxoplasma anti-IgG Conjugate into all wells except in the blank wells ( A1/A2). Cover with foil. 10. Following the instructions 6. – 11. mentioned in the package insert of Toxoplasma gondii IgG ELISA, [REF] TOXG0460. 3 8. RESULTS 8.1. Assay validation criteria In order for an assay to be considered valid, the following criteria must be met: Substrate blank in A1/A2: Absorbance value lower than 0.100. Performance control in B1/B2: Avidity (%): exact value and range are indicated on the label If these criteria are not met, the test is not valid and must be repeated. 8.2. Calculation of Results With patient samples having an absorbance value lower than the cut-off determined by the regular NovaTec Toxoplasma gondii IgG ELISA you may not proceed. These samples contain no antibodies to Toxoplasma at all or a concentration of Toxoplasma IgG antibody that is low to evaluate IgG avidity. For each patient sample or control calculate the ratio between the absorbance of the well dispensed with Avidity reagent and the absorbance of the well dispensed with Washing buffer multiplied by 100: Absorbance (sample or control) Avidity reagent x100 = Avidity(%) Absorbance (sample or control) Washing buffer (diluted 1 +19) Samples or controls with an absorbance greater than the measuring range of the ELISA reader (over f / error) at 450 nm the absorbance of these samples must be read at 405 nm. The calculation of the Avidity (%) is the same as with 450 nm. 8.3. Interpretation of Results Avidity (%) > 40 Toxoplasmosis antibody with high avidity -- Past infection Avidity (%) ≤40 Toxoplasmosis antibody with low avidity - - Acute or recent infection 9. SPECIFIC PERFORMANCE CHARACTERISTICS 9.1. Precision Intraassay Sample n Mean avidity(%) CV (%) High avidity serum 24 89.0 4.1 High avidity serum 22 77.1 4.0 Low avidity serum 20 24.7 4.6 Interassay Sample n Mean avidity(%) CV (%) High avidity serum 6 88.8 2.4 High avidity serum 6 78.8 3.2 Low avidity serum 6 25.8 3.9 9.2. Performance Characteristics The NovaTec Toxoplasma gondii IgG Avidity Test has been evaluated for use in Toxoplasmosis with acute and past infection sera. A total number of 69 patient samples were tested. These sera were supplied by the Institute of Parasitology, University Bonn. Total: 69 patient sera Acut Infection Past Infection Total Inst. of Parasitology 25 44 69 NovaTec Avidity Test 23 41 64 Discrepancy sera: NovaTec Avidity Test 3 f Acut 2 f Past 5 Agreement 92% 93.2% 92.7% These five discrepant sera were retested in an Avidity ELISA of another manufacturer. Four sera were in accordance to NovaTec Avidity ELISA and 1 serum was different to the NovaTec Test. 9.3. Interferences / Cross reactivity Regarding the interferences and cross reactivity please refer to the package insert of Toxoplasma gondii IgG [REF] TOXG0460. Note: The results refer to the groups of samples investigated; these are not guaranteed specifications. 10. LIMITATIONS OF THE PROCEDURE Bacterial contamination or repeated freeze-thaw cycles of the specimen may affect the absorbance values. Diagnosis of an infectious disease should not be established on the basis of a single test result. A precise diagnosis should take into consideration clinical history, symptomatology as well as serological data. In immunocompromized patients and newborns serological data only have restricted value. A result of high avidity can not exclude the possibility of a recent infection. 11. PRECAUTIONS AND WARNINGS In compliance with article 1 paragraph 2b European directive 98/79/EC the use of the in vitro diagnostic medical devices is intended by the manufacturer to secure suitability, performances and safety of the product. Therefore the test procedure, the information, the precautions and warnings in the instructions for use have to be strictly followed. The use of the testkits with analyzers and similar equipment has to be validated. Any change in design, composition and test procedure as well as for any use in combination with other products not approved by the manufacturer is not authorized; the user himself is responsible for such changes. The manufacturer is not 4 liable for false results and incidents for these reasons. The manufacturer is not liable for any results by visual analysis of the patient samples. Only for in-vitro diagnostic use. All components of human origin used for the production of these reagents have been tested for anti-HIV antibodies, anti-HCV antibodies and HBsAg and have been found to be non-reactive. Nevertheless, all materials should still be regarded and handled as potentially infectious. uploads/Sante/ kit-anti-toxo-igg.pdf